Tengsheng Bo Pharmaceuticals was established and received $260 million in financing from six well-known institutions

Innovative drug developer Teng Shengbo Pharmaceuticals today announced the official establishment and completed a $260 million financing. The round of financing is led by ARCH Venture Partners, Tong and Cheng Capital, Boyu Capital, Yunfeng Fund, Sequoia Capital and Blue Pool Capital.
is understood that TengShengBo Drug will focus on the treatment of chronic diseases and infectious diseases innovative drug development and production, dedicated to meeting the needs of Patients and public health in China.
announced the financing, TengshengBo Pharmaceuticals announced that it has reached an important strategic partnership with a number of enterprises to accelerate the development of infectious disease drugs in China, through advanced technology and data to help the development of China's public health system, thereby benefiting the vast number of patients.
First, in partnership with Vir Biotechnology, a leading U.S. infectious disease innovation drug developer, Tensenberg Pharmaceuticals will receive exclusive rights to up to four innovative drugs for infectious diseases in Greater China for future treatment of a wide range of infectious diseases.
Second, Tengsheng Bo Pharmaceuticals and Alibaba Group's Ali Health pioneered digital data sharing collaboration model, can better explore disruptive innovative methods, found the most valuable evidence of efficacy, to optimize clinical research and commercial development processes, and continuously enhance the clinical experience of patients trying new therapies. This strategic partnership will help TengShengBo Drug to further explore innovative ways to accelerate access to new drugs, but also to help patients use drugs rationally.
third, Tengshengbo Pharmaceuticals has also signed memorandums of understanding with Pharmaceutical Mingkangde and Pharmaceutical Biology, so that it can give priority to the use of its international leading research and development production technology capability platform to accelerate the development of breakthrough innovative drugs in China.
past decade, innovative drug development has been carried out at an unprecedented rate and many life-threatening diseases have been cured, with profound implications for human health. Dr. Hong Zhi, Co-Founder, President and CEO of Tengsheng Bo Pharmaceuticals, said, "Providing innovative drugs to Chinese patients is not only an opportunity, but also an opportunity to significantly improve public health." Patients in China need faster and more affordable access to innovative drugs and therapies, and China already has a good public health infrastructure and advanced digital data technology on a large scale. (Sina Pharmaceuticals)